AnGes MG Finally Starts Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
Tokyo, Japan, Oct 4, 2005 - (JCNN) - AnGes MG has commenced a phase I clinical trial of NF-kappa B decoy oligodeoxynucleotide. The clinical trial aims to seek the feasibility of NF-kappa B decoy oligodeoxynucleotide in the treatment of atopic dermatitis.The company has partnered with Alfresa Pharma in the trial. Currently, there are over 1.4 million people with atopic dermatitis in Japan, and no effective treatment for severe atopic dermatitis has yet to be established.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
 Printer friendly
 Cite/link
 Email
 Feedback
| |
| Publication: | JCNN News Summaries |
|---|---|
| Date: | Oct 5, 2005 |
| Words: | 91 |
| Previous Article: | ESPEC Releases Carbon Dioxide Incubator with Dry-Heat Sterilizing Function. |
| Next Article: | JVC Develops Base Technologies for Next-generation Optical Wireless Access System. |